264 filings
10-Q
2024 Q1
VKTX
Viking Therapeutics Inc
Quarterly report
24 Apr 24
8:42pm
8-K
VKTX
Viking Therapeutics Inc
24 Apr 24
Viking Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update
4:05pm
ARS
2023 FY
VKTX
Viking Therapeutics Inc
5 Apr 24
Annual report to shareholders
4:15pm
DEFA14A
VKTX
Viking Therapeutics Inc
5 Apr 24
Additional proxy soliciting materials
4:10pm
DEF 14A
VKTX
Viking Therapeutics Inc
Definitive proxy
5 Apr 24
4:05pm
8-K
et333ahklvilg4j0 oz
26 Mar 24
Viking Therapeutics Announces Results from Phase 1 Clinical Trial of Oral Tablet Formulation of Dual GLP-1/GIP Receptor Agonist VK2735
7:08am
8-K
sfsx mmdms
4 Mar 24
Other Events
4:52pm
424B5
a4q67
1 Mar 24
Prospectus supplement for primary offering
4:13pm
8-K
ddxnf70294c nxcnb9
1 Mar 24
Viking Therapeutics Announces Pricing of $550 Million Public Offering of Common Stock
4:05pm
424B5
fxwbx07ttf5dzc3
27 Feb 24
Prospectus supplement for primary offering
5:21pm
8-K
pm7n8bex fxi2
27 Feb 24
Viking Therapeutics Announces Positive Top-Line Results from Phase 2 VENTURE Trial of Dual GLP-1/GIP Receptor Agonist VK2735 in Patients with Obesity
7:04am
S-8
blpq8s8rpw qwo
7 Feb 24
Registration of securities for employees
5:33pm
8-K
4tegqwscd9yqzstzfrw
7 Feb 24
Viking Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Corporate Update
4:09pm
8-K
1uv602s eey0a9
25 Oct 23
Viking Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update
4:24pm
S-3ASR
tqy1vs67glsvg
26 Jul 23
Automatic shelf registration
5:26pm
8-K
xvzio knjaf53ixs
26 Jul 23
Viking Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update
4:23pm
8-K
stgyw wtv5qog7
14 Jun 23
Submission of Matters to a Vote of Security Holders
4:23pm